Drug Profile
BO 112
Alternative Names: BO-112; Nanoplexed Poly IC BO-112; Nanoplexed Polyinosinic:Polycytidylic Acid BO-112Latest Information Update: 08 Feb 2024
Price :
$50
*
At a glance
- Originator Bioncotech Therapeutics
- Developer Highlight Therapeutics; Merck Sharp & Dohme; UCLAs Jonsson Comprehensive Cancer Center
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action DDX58 protein stimulants; IFIH1 protein stimulants; Immunostimulants; PMAIP1 protein stimulants; Toll-like receptor 3 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer; Gastric cancer; Malignant melanoma
- Phase I/II Non-small cell lung cancer
- Phase I Liver cancer
- No development reported Soft tissue sarcoma; Solid tumours
Most Recent Events
- 08 Feb 2024 Bioncotech Therapeutics completes a phase I trial in Solid tumours (Monotherapy, Combination therapy, Second-line therapy or greater) in Spain (Intratumoural) (NCT02828098)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Soft tissue sarcoma(Combination therapy) in USA (Intratumoural, Injection)
- 13 Jun 2022 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Spain (Intratumoural) (NCT05265650)